Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 351,771 shares at $66.00 ($23.3M) on 2024-01-17, disclosed to the SEC on 2024-01-18.
Scheduled sale ($23.3M) by Chairman, President & CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $66.38 | 3,500 | $232K | 1.0% |
| 2 | $66.38 | 3,500 | $232K | 1.0% |
| 3 | $67.25 | 65,979 | $4.4M | 19.0% |
| 4 | $67.25 | 65,979 | $4.4M | 19.0% |
| 5 | $67.76 | 5,882 | $399K | 1.7% |
| 6 | $67.76 | 5,882 |
| $399K |
| 1.7% |
| 7 | $66.00 | 30,633 | $2.0M | 8.7% |
| 8 | $66.66 | 17,451 | $1.2M | 5.0% |
| 9 | $66.66 | 17,451 | $1.2M | 5.0% |
| 10 | $65.19 | 67,597 | $4.4M | 18.9% |
| 11 | $65.19 | 67,597 | $4.4M | 18.9% |
| 12 | $66.25 | 320 | $21K | 0.1% |
| Total | $66.29 avg | 351,771 | $23.3M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |